• Consensus Rating: N/A
  • Consensus Price Target: $2.00
  • Forecasted Upside: -30.31%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.87
▼ -0.15 (-4.97%)

This chart shows the closing price for IRIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IRIDEX Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IRIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IRIX

Analyst Price Target is $2.00
▼ -30.31% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for IRIDEX in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a -30.31% upside from the last price of $2.87.

This chart shows the closing price for IRIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in IRIDEX. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2023Stifel NicolausLower Target$3.00 ➝ $2.00Low
8/26/2022Stifel NicolausDowngradeBuy ➝ Hold$5.00 ➝ $3.00Low
5/12/2021Roth CapitalBoost TargetBuy$9.00 ➝ $11.00High
3/3/2021Roth CapitalBoost TargetBuy$6.00 ➝ $9.00Low
1/13/2021Roth CapitalBoost TargetBuy$5.50 ➝ $6.00High
5/12/2020Stifel NicolausLower TargetBuy$5.00 ➝ $4.00High
3/16/2020Roth CapitalReiterated RatingBuyMedium
(Data available from 4/21/2019 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/23/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/21/2024

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
IRIDEX logo
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $2.87
Low: $2.86
High: $3.01

50 Day Range

MA: $2.77
Low: $2.35
High: $3.53

52 Week Range

Now: $2.87
Low: $1.31
High: $3.65

Volume

50,079 shs

Average Volume

50,088 shs

Market Capitalization

$46.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of IRIDEX?

The following Wall Street analysts have issued reports on IRIDEX in the last twelve months: Stifel Nicolaus, and StockNews.com.
View the latest analyst ratings for IRIX.

What is the current price target for IRIDEX?

1 Wall Street analysts have set twelve-month price targets for IRIDEX in the last year. Their average twelve-month price target is $2.00, suggesting a possible downside of 30.3%. Stifel Nicolaus has the highest price target set, predicting IRIX will reach $2.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $2.00 for IRIDEX in the next year.
View the latest price targets for IRIX.

What is the current consensus analyst rating for IRIDEX?

IRIDEX currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IRIX.

What other companies compete with IRIDEX?

How do I contact IRIDEX's investor relations team?

IRIDEX's physical mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider's listed phone number is (650) 940-4700 and its investor relations email address is [email protected]. The official website for IRIDEX is www.iridex.com. Learn More about contacing IRIDEX investor relations.